Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05438797
Other study ID # 2022DZKY-039-02
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date April 2, 2021
Est. completion date April 2024

Study information

Verified date June 2022
Source Jinling Hospital, China
Contact Xinbo Wang, MD
Phone 13505172912
Email wxinbo2008@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.


Description:

This is a single arm, open-label, single-center study.This study is indicated for advanced relapse-refractory or metastatic pancreatic cancer.The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. Primary objective is to explore the safety, main consideration is dose-related safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 3
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Aged=18 years old and =70 years old when signing the informed consent; regardless of gender;Body weight>40kg. 2. Patients with advanced recurrent refractory or metastatic pancreatic cancer who have failed at least one standard treatment or who are unable to tolerate, unwilling or financially unable to receive standard treatment. 3. The subject will have at least one eligible tissue or sample available for cell preparation. 4. Patients with brain metastatic lesions who are asymptomatic , the diameter of a single lesion =1 cm, and the number of lesions =3 may be eligible. 5. Patients should have good clinical presentation status (ECOG 0 or 1). 6. HIV antibody and treponema pallidum antibody was negative. 7. Vital organ function test (do not accept any cytokines or blood transfusion within 14 days prior to test): 1)absolute neutrophil count (ANC) =1000/µL; 2)White blood cell count (WBC) 3000/µL; 3)Platelet count (PLT) 75,000 /µL; 4)Hemoglobin (Hb) > 8.0 g/dL; 5) Coagulation: activated partial thromboplastin time (APTT) =1.5×ULN, international normalized ratio (INR) or Prothrombin time (PT)=1.5×ULN; 6) Liver functions: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =5.0 ×ULN; 7) Liver functions:Total bilirubin (TBIL)<1.5×ULN (baseline value normal); <1.0 - 1.5×ULN( baseline value abnormal); If diagnosed as Gilbert syndrome, =3.0 mg/dL; The test results should prevail of the center laboratory ; 8)Renal function: eGFR>60 mL/min or 6-24 hours CrCl>60 mL/min; 9)Heart Doppler ultrasound:LVEF=50%; 8.Non-surgically sterilized women of child-bearing age are required to consent to use at least one medically approved contraceptive method during the study and one year after completion.Women of child-bearing age must be negative for pregnancy test at 7 days before initiation of the treatment.Male subjects must agree to use medically approved contraception from the time they sign the informed consent form to the time they leave the study. 9.Expected survival no less than 3 months. Exclusion Criteria: 1. Pregnancy or lactation; 2. Active infections requiring systemic anti-infective therapy ( topical antibiotics excepted); 3. Patients who are taking systemic steroids or immunosuppressive drugs; 4. Hepatitis B (hepatitis B surface antigen [HbsAg] and/or core antibody [HbcAb] positive, HBV-DNA<1000 copies /mL can be included); 5. Hepatitis C ( HCV antibody positive and HCV-RNA positive); 6. Serious autoimmune diseases or immunodeficiency disease, such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (eg., Wegener's granulomatosis); 7. Allergic:Severe allergies to the drugs used in the study; Contraindications for IL-2 used ; 8. Patients with other active malignancies within the past 5 years, but not those who were clinically cured within 5 years of diagnosis of cervical epithelial carcinoma, basal or squamous skin cancer, superficial bladder cancer, breast cancer in situ and did not require follow-up; 9. Any mental diseases, including dementia and changes in mental status that may influence the understanding about the informed consent and questionnaire; 10. Unstable disease of heart head blood-vessel, including but not limited to, the heart cerebrovascular accident or transient ischemic (within 6 months prior to screening) myocardial infarction (within 6 months prior to screening)/vein thrombosis (within 6 months prior to screening, require surgery to repair the aortic aneurysm or proximal artery thrombosis group shall not enter into) unstable angina New York Heart Association (NYHA) Classification= III congestive heart failure severe arrhythmias poorly controlled by medications and severe hypertension that cannot be controlled by treatment or is untreated (systolic pressure=160 mmHg and/or diastolic pressure=100 mmHg ); 11. Patients with severe interstitial pneumonia other active pneumonia or bronchospasm and other respiratory diseases that seriously affect lung function; 12. Patients with active gastrointestinal bleeding; 13. Had major surgery within 1 month prior to screening or during the study ; 14. Enrolled in other clinical trials (including other adoptive cell immunotherapies) and used the investigational drug within 1 month prior to screening. 15. Have received live attenuated vaccine within 1 month prior to screening or are expected to receive live attenuated vaccine during the study ; 16. Received any systemic antitumor drug therapy (including chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy or other biotherapy) within 4 weeks prior to pretreatment; 17. Have previously received allogeneic bone marrow transplantation or solid organ transplantation; 18. Alcohol, drug or substance abuse; 19. Judged as serious uncontrollable diseases by the researchers, or other conditions that may interfere with the treatment and therefore being ineligible.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Adoptive TIL-TCM transfer therapy
Abraxane:100-200 mg/m2,QD×1D;Cyclophosphamide:15-35 mg/kg/d,QD×2D. Biological: Adoptive TIL-TCM transfer therapy

Locations

Country Name City State
China Jinling Hospital Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Sizhen Wang Shanghai Biomed-union Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer Baseline up to 28 days after TIL-TCM cells infusion
Primary Maximum Tolerated Dose(MTD) To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancer Baseline up to 28 days after TIL-TCM cells infusion
Primary incidence of adverse events( AE )and Serious adverse events(SAE) Adverse events assessed according to NCI-CTCAE v5.0 criteria. up to 72 weeks after TIL-TCM cells infusion
Secondary Overall response rate (ORR) ORR is defined as the percentage of patients who have a clinical response (objective tumor regression).ORR is computed by: the sum of the number of patients with Complete Response (CR) and number of patients with Partial Response (PR) / total number of patients. The total number of patients is the sum of the number of patients with CR, PR, stable disease (SD) or progressive disease (PD). The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) is used as the criteria to determine whether a tumor disappears (CR), shrinks (PR), stays the same (SD) or gets bigger (PD). 18 months
Secondary Duration of response (DOR) DOR is the time between the initial response to treatment per RECIST v1.1 and subsequent disease progression among patients achieving Complete Response (CR) or Partial Response (PR). RECIST v1.1 is used as the criteria to determine whether a tumor disappears (CR) or shrinks (PR). 18 months
Secondary Progression-free survival (PFS) PFS is the length of time from the date patient enrolled in to the date on which tumor progresses or the patient dies for any cause. 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Not yet recruiting NCT03662035 - Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05085548 - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies Phase 1
Recruiting NCT06111274 - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04137536 - A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Phase 1
Completed NCT04617067 - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Recruiting NCT04104672 - A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Phase 1
Not yet recruiting NCT05100329 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT02101580 - Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Phase 1
Not yet recruiting NCT06329947 - A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD Phase 2
Recruiting NCT02135822 - Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Phase 2
Recruiting NCT04803851 - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT03415802 - Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05162118 - Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04643405 - APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT03889795 - Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Phase 1
Completed NCT01303172 - A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06422156 - SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT04931381 - Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer Phase 3